Oct, 1, 2023

Vol.30 No.2, pp. 84-88


Review

  • Korean Journal of Biological Psychiatry
  • Volume 4(1); 1997
  • Article

Review

Korean Journal of Biological Psychiatry 1997;4(1):132-5. Published online: Jan, 1, 1997

Psychosis in Parkinson’s Disease-Treatment with 5-HT Receptor Antagonist-

  • Seong-Beom Koh, MD;Kun-Woo Park, MD, PhD; and Dae-Hie Lee, MD, PhD
    Department of Neurology, College of Medicine, Korea University, Seoul, Korea
Abstract

Current treatment strategies for levodopa-induced psychosis in advanced Parkinson’s disease have had limited success. Reduction or discontinuation of levodopa and coadministration with dopamine-blocking neuroleptics may attenuate the psychotic symptoms, but these strategies are associated with worsening of parkinsonian symptoms. Administration of 5-HT3 receptor antagonist;ondansetron, a newer strategy to attenuate psychosis of Parkinson’disease without motor deterioration was introduced. A 41-year-old young-onset male, who was diagnosed as Parkinson’s disease 7 years ago, was treated with levodopa therapy, and had levodopa-induced psychosis(delusion, hallucination, paranoid, insomnia). After trial of ondansetron, he showed improvement in the Brief Psychiatric Rating Scale(from 21 points to 9 points) in spite of increasing the dosage of levodopa. With ondansetron, we could increase the dosage of levodopa without psychotic complications(esp, hallucination), and he showed improvement in the motor fluctuation.

Keywords Levodopa-induced psychosis;5-HT3 receptor antagonist;Ondansetron.